Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status

Fig. 3

There was no difference in RFS between patients treated with or without adjuvant chemotherapy in Mt high-risk patients (p = 0.201, (a)). In Wt high-risk patients, RFS was significantly better in patients who received adjuvant chemotherapy than in those who did not receive adjuvant chemotherapy (p < 0.001, (b))

Back to article page